RU2010106522A - POLYFUNCTIONAL POLYHEMOGLOBIN-ENZYME COMPLEX - Google Patents
POLYFUNCTIONAL POLYHEMOGLOBIN-ENZYME COMPLEX Download PDFInfo
- Publication number
- RU2010106522A RU2010106522A RU2010106522/15A RU2010106522A RU2010106522A RU 2010106522 A RU2010106522 A RU 2010106522A RU 2010106522/15 A RU2010106522/15 A RU 2010106522/15A RU 2010106522 A RU2010106522 A RU 2010106522A RU 2010106522 A RU2010106522 A RU 2010106522A
- Authority
- RU
- Russia
- Prior art keywords
- molecules
- polyhemoglobin
- tetramers
- total number
- complex
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Полифункциональный полигемоглобин-ферментный комплекс, состоящий из молекул полигемоглобина различного состава с молекулярной массой в диапазоне 300-3300 кДа, полученных с использованием глутарового альдегида; в комплексе 90-99,99% от общего числа молекул полигемоглобина составляют молекулы полиоксигемоглобина, полученные из тетрамеров бычьего оксигемоглобина (HbO2), к которому с помощью глутарового альдегида пришиты ферменты супероксиддисмутаза и каталаза, взятые в следующем диапазоне:общее количество тетрамеров в полиоксигемоглобине:СОД равно 5:1-5·103:1 и общее количество тетрамеров в полиоксигемоглобине:каталаза равно 5:1-5·103:1 соответственно; в комплексе 0,009-9% от общего числа молекул полигемоглобина составляют молекулы полигемоглобина, полученные из NO-производных тетрамеров бычьего гемоглобина; в комплексе 0,001-1% от общего числа молекул полигемоглобина составляют молекулы полигемоглобина, полученные из тетрамеров бычьего карбоксигемоглобина; количество молекул глутарового альдегида, используемое для полимеризации белков, должно быть выше количества полимеризуемых молекул в 4-24 раза. A polyfunctional polyhemoglobin-enzyme complex consisting of polyhemoglobin molecules of various compositions with a molecular weight in the range of 300-3300 kDa obtained using glutaraldehyde; In the complex, 90-99.99% of the total number of polyhemoglobin molecules are polyoxyhemoglobin molecules obtained from bovine oxyhemoglobin (HbO2) tetramers, to which superoxide dismutase and catalase enzymes are sewn using the following range: total number of tetramers in polyoxy Hemoglobin: equal to 5: 1-5 · 103: 1 and the total number of tetramers in polyoxyhemoglobin: catalase is 5: 1-5 · 103: 1, respectively; in the complex, 0.009-9% of the total number of polyhemoglobin molecules are polyhemoglobin molecules obtained from NO-derivatives of bovine hemoglobin tetramers; in the complex, 0.001-1% of the total number of polyhemoglobin molecules are polyhemoglobin molecules obtained from bovine carboxyhemoglobin tetramers; the number of glutaraldehyde molecules used for the polymerization of proteins should be 4-24 times higher than the number of polymerized molecules.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2010106522/15A RU2432172C1 (en) | 2010-02-24 | 2010-02-24 | Polyfunctional polyhemoglobin-enzyme complex |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2010106522/15A RU2432172C1 (en) | 2010-02-24 | 2010-02-24 | Polyfunctional polyhemoglobin-enzyme complex |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010106522A true RU2010106522A (en) | 2011-08-27 |
RU2432172C1 RU2432172C1 (en) | 2011-10-27 |
Family
ID=44756329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010106522/15A RU2432172C1 (en) | 2010-02-24 | 2010-02-24 | Polyfunctional polyhemoglobin-enzyme complex |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2432172C1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113813372A (en) * | 2021-09-26 | 2021-12-21 | 云锦华彰(北京)生物科技有限公司 | Heme composition, pharmaceutical composition and application thereof |
-
2010
- 2010-02-24 RU RU2010106522/15A patent/RU2432172C1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113813372A (en) * | 2021-09-26 | 2021-12-21 | 云锦华彰(北京)生物科技有限公司 | Heme composition, pharmaceutical composition and application thereof |
Also Published As
Publication number | Publication date |
---|---|
RU2432172C1 (en) | 2011-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015515462A5 (en) | ||
RU2534564C3 (en) | MULTI-SPECIFIC BINDING ANTIGEN MOLECULE WHICH HAS AN ALTERNATIVE FUNCTION TO THE FUNCTION OF THE BLOOD COAGING FACTOR VIII | |
PE20071327A1 (en) | JOINT CULTURE OF PLACENTARY STEM CELLS AND STEM CELLS FROM A SECOND SOURCE | |
WO2009135853A3 (en) | Encapsulation of biologically active agents | |
WO2011084808A3 (en) | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases | |
WO2014078688A3 (en) | Recombinant adenoviruses and use thereof | |
NZ607069A (en) | Modified relaxin polypeptides and their uses | |
EA202091105A1 (en) | GUANILATCYCLASE COMPOSITIONS AND METHODS FOR TREATMENT OF CONGENITAL LEBER AMAVROSIS TYPE 1 (LCA1) | |
WO2012064709A3 (en) | Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity | |
TN2014000236A1 (en) | Use of chemically modified heparin derivates in sickle cell disease | |
EA201001569A1 (en) | Incapsulation of biologically active agents | |
EA201390720A1 (en) | METHODS TO IMPROVE TISSUE OXYGENATION, DANGEROUS HAZARDS | |
WO2012053823A3 (en) | Fusion protein having factor ix activity | |
RU2010106522A (en) | POLYFUNCTIONAL POLYHEMOGLOBIN-ENZYME COMPLEX | |
CA2908236C (en) | Diaspirin crosslinked pegylated hemoglobin | |
EA201100653A1 (en) | LIGANDS CONNECTING INTERLAYKIN-13 (IL-13) | |
PH12017550132A1 (en) | Beta-casein a2 and antioxidant capacity | |
Claudia et al. | Laccase induced maize bran arabinoxylan gels: Structural and rheological properties | |
ATE531445T1 (en) | MEMBRANES WITH IMPROVED PERFORMANCE | |
WO2009135854A3 (en) | Encapsulation of biologically active agents | |
EA201591095A1 (en) | PROTEIN SLURP-1 FOR USE IN THE TREATMENT OF EYE DISEASES | |
RU2012122468A (en) | COMPOSITION FOR TREATMENT OF SKIN INJURIES | |
RU2011114963A (en) | TRANSBUKAL OINTMENT CONTAINING INSULIN AND LIPOSOMES | |
RU2019109061A (en) | Composition for the treatment of gynecological and proctological diseases accompanied by oxidative stress | |
WO2011106674A3 (en) | Use of endogenous antioxidant proteins in the treatment of stroke |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130225 |